And, accordingly, designing effective combination therapies using ACSL4 and mTOR inhibitors together with agents targeting key molecular elements involved in breast cancer relies heavily on the identification of predictive markers that may provide the basis for patient therapy. Here, ACSL4 is linked to breast cancer.